Orforglipron , an investigative and oral GLP-1 drug, appears to enable adults with obesity and Type 2 diabetes to achieve significantly more weight loss and improvement in blood… read more.
Novo Nordisk presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, The Liver Meeting 2025, in Washington, D.C., evaluating the effects… read more.
At ObesityWeek taking place in Atlanta, US, Novo Nordisk presented new findings from the STEP UP phase IIIb trial. It showed that, in addition to losing an average… read more.
A new analysis of the SELECT trial – the largest and longest clinical trial to date examining the cardiovascular benefits of semaglutide (a medication used to support weight… read more.
The prevalence of obesity in the United States could rise sharply under a new definition of obesity released earlier this year by the Lancet Diabetes and Endocrinology Commission. Researchers… read more.
Mayo Clinic researchers have developed a genetic test that can help predict how people will respond to weight loss medications such as GLP-1s. The test estimates an individual’s… read more.
More than half of all adults without diabetes who began taking semaglutide discontinued treatment within a year, according to new research on Danish patients. The population-wide study was… read more.
Less than half of England has access to tirzepatide (Mounjaro) through their GP, despite the NHS roll-out of the weight-loss jab officially starting over two months ago, an… read more.
NICE (UK): Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: i)… read more.
New research has found that the use of GLP-1 receptor agonists*, a class of medications commonly prescribed for patients with obesity and diabetes, reduces the environmental footprint of… read more.
When given nutritionally matched diets, participants lost twice as much weight eating minimally processed foods compared to ultra-processed foods, suggesting that cutting down on processing could help to… read more.
Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to a new RAND report. Surveying a nationally… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
